OBJECTIVE: Lung transplantation has become accepted therapy for end-stage pulmonary disease. The objective of this study was to review a single-institution experience of adult lung transplants. METHODS: We reviewed 1000 adult lung transplants that were performed at Washington University between July 1988 and January 2009. RESULTS: Transplants were performed for emphysema (52%), cystic fibrosis (18.2%), pulmonary fibrosis (16.1%), and pulmonary vascular disease (7.2%). Overall recipient age was 48 ± 13 years with an increase from 43 ± 12 years (July 1988-November 1993) to 50 ± 14 years (June 2005-January 2009). Overall incidence of primary graft dysfunction was 22.1%. Hospital mortality was higher for patients who had primary graft dysfunction (primary graft dysfunction, 13.6%; no primary graft dysfunction, 4%; P < .001). Freedom from bronchiolitis obliterans syndrome was 84% at 1 year, 38.2% at 5 years, and 12.2% at 10 years. Survival at 1, 5, 10, and 15 years was 84%, 56.4%, 32.2%, and 17.8%, respectively. Five-year survival improved from 49.6% (July 1988-November 1993) to 62.1% (October 2001-June 2005). Primary graft dysfunction was associated with lower survival at 1, 5, and 10 years (primary graft dysfunction: 72.8%, 43.9%, and 18.7%, respectively; no primary graft dysfunction: 87.1%, 59.8%, and 35.7%, respectively, P < .001) and lower rates of freedom from bronchiolitis obliterans syndrome (primary graft dysfunction: 78%, 27.5%, and 8.5%, respectively; no primary graft dysfunction: 85.4%, 40.7%, and 13.1%, respectively, P = .007). CONCLUSIONS: Five-year survival has improved over the study period, but long-term outcomes are limited by bronchiolitis obliterans syndrome. Primary graft dysfunction is associated with higher rates of bronchiolitis obliterans syndrome and impaired short- and long-term survival. A better understanding of primary graft dysfunction and bronchiolitis obliterans syndrome is critical to improve outcomes.
OBJECTIVE: Lung transplantation has become accepted therapy for end-stage pulmonary disease. The objective of this study was to review a single-institution experience of adult lung transplants. METHODS: We reviewed 1000 adult lung transplants that were performed at Washington University between July 1988 and January 2009. RESULTS: Transplants were performed for emphysema (52%), cystic fibrosis (18.2%), pulmonary fibrosis (16.1%), and pulmonary vascular disease (7.2%). Overall recipient age was 48 ± 13 years with an increase from 43 ± 12 years (July 1988-November 1993) to 50 ± 14 years (June 2005-January 2009). Overall incidence of primary graft dysfunction was 22.1%. Hospital mortality was higher for patients who had primary graft dysfunction (primary graft dysfunction, 13.6%; no primary graft dysfunction, 4%; P < .001). Freedom from bronchiolitis obliterans syndrome was 84% at 1 year, 38.2% at 5 years, and 12.2% at 10 years. Survival at 1, 5, 10, and 15 years was 84%, 56.4%, 32.2%, and 17.8%, respectively. Five-year survival improved from 49.6% (July 1988-November 1993) to 62.1% (October 2001-June 2005). Primary graft dysfunction was associated with lower survival at 1, 5, and 10 years (primary graft dysfunction: 72.8%, 43.9%, and 18.7%, respectively; no primary graft dysfunction: 87.1%, 59.8%, and 35.7%, respectively, P < .001) and lower rates of freedom from bronchiolitis obliterans syndrome (primary graft dysfunction: 78%, 27.5%, and 8.5%, respectively; no primary graft dysfunction: 85.4%, 40.7%, and 13.1%, respectively, P = .007). CONCLUSIONS: Five-year survival has improved over the study period, but long-term outcomes are limited by bronchiolitis obliterans syndrome. Primary graft dysfunction is associated with higher rates of bronchiolitis obliterans syndrome and impaired short- and long-term survival. A better understanding of primary graft dysfunction and bronchiolitis obliterans syndrome is critical to improve outcomes.
Authors: Y Liu; W Li; H P Luehmann; Y Zhao; L Detering; D H Sultan; H-M Hsiao; A S Krupnick; A E Gelman; C Combadiere; R J Gropler; S L Brody; D Kreisel Journal: Am J Transplant Date: 2016-07-14 Impact factor: 8.086
Authors: David J Hall; Maher Baz; Michael J Daniels; Edward Denmark Staples; Charles T Klodell; Lyle L Moldawer; Thomas M Beaver Journal: Interact Cardiovasc Thorac Surg Date: 2012-07-19
Authors: Jun Cai; Ricardo Gehrau; Zhenxiao Tu; Victoria Leroy; Gang Su; Junyi Shang; Valeria R Mas; Amir Emtiazjoo; Andres Pelaez; Carl Atkinson; Tiago Machuca; Gilbert R Upchurch; Ashish K Sharma Journal: J Heart Lung Transplant Date: 2020-09-28 Impact factor: 10.247
Authors: Alexander Sasha Krupnick; Xue Lin; Wenjun Li; Ryuiji Higashikubo; Bernd H Zinselmeyer; Hollyce Hartzler; Kelsey Toth; Jon H Ritter; Mikhail Y Berezin; Steven T Wang; Mark J Miller; Andrew E Gelman; Daniel Kreisel Journal: J Clin Invest Date: 2014-02-24 Impact factor: 14.808
Authors: Mary E Huerter; Ashish K Sharma; Yunge Zhao; Eric J Charles; Irving L Kron; Victor E Laubach Journal: Ann Thorac Surg Date: 2016-04-22 Impact factor: 4.330
Authors: Benjamin J Kopecky; Christian Frye; Yuriko Terada; Keki R Balsara; Daniel Kreisel; Kory J Lavine Journal: Am J Transplant Date: 2020-01-29 Impact factor: 8.086
Authors: Jessica H Spahn; Wenjun Li; Alejandro C Bribriesco; Jie Liu; Hua Shen; Aida Ibricevic; Jie-Hong Pan; Bernd H Zinselmeyer; Steven L Brody; Daniel R Goldstein; Alexander S Krupnick; Andrew E Gelman; Mark J Miller; Daniel Kreisel Journal: J Immunol Date: 2015-03-11 Impact factor: 5.422
Authors: Cynthia E Wagner; Nicolas H Pope; Eric J Charles; Mary E Huerter; Ashish K Sharma; Morgan D Salmon; Benjamin T Carter; Mark H Stoler; Christine L Lau; Victor E Laubach; Irving L Kron Journal: J Thorac Cardiovasc Surg Date: 2015-07-30 Impact factor: 5.209